1. Itaconate drives mtRNA-mediated type I interferon production through inhibition of succinate dehydrogenase.
- Author
-
O'Carroll SM, Peace CG, Toller-Kawahisa JE, Min Y, Hooftman A, Charki S, Kehoe L, O'Sullivan MJ, Zoller A, Mcgettrick AF, Day EA, Simarro M, Armstrong N, Annes JP, and O'Neill LAJ
- Subjects
- Humans, Interferon-Induced Helicase, IFIH1 metabolism, Animals, Mice, Voltage-Dependent Anion Channel 1 metabolism, Voltage-Dependent Anion Channel 1 antagonists & inhibitors, Macrophages metabolism, Macrophages drug effects, RNA, Double-Stranded metabolism, Citric Acid Cycle drug effects, DEAD Box Protein 58 metabolism, Mitochondria metabolism, Mitochondria drug effects, Receptors, Immunologic, Succinates pharmacology, Succinates metabolism, Succinate Dehydrogenase metabolism, Succinate Dehydrogenase antagonists & inhibitors, Interferon Type I metabolism, RNA, Mitochondrial metabolism
- Abstract
Itaconate is one of the most highly upregulated metabolites in inflammatory macrophages and has been shown to have immunomodulatory properties. Here, we show that itaconate promotes type I interferon production through inhibition of succinate dehydrogenase (SDH). Using pharmacological and genetic approaches, we show that SDH inhibition by endogenous or exogenous itaconate leads to double-stranded mitochondrial RNA (mtRNA) release, which is dependent on the mitochondrial pore formed by VDAC1. In addition, the double-stranded RNA sensors MDA5 and RIG-I are required for IFNβ production in response to SDH inhibition by itaconate. Collectively, our data indicate that inhibition of SDH by itaconate links TCA cycle modulation to type I interferon production through mtRNA release., Competing Interests: Competing interests: L.A.J.O. is a paid consultant for Sitryx Therapeutics, Sail Biomedicines and Montai Health. The other authors declare no competing interests., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF